
## Nathalie Lassau

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11084285/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer. Journal of Clinical Oncology, 2006, 24, 25-35.	1.6	1,088
2	Imaging biomarker roadmap for cancer studies. Nature Reviews Clinical Oncology, 2017, 14, 169-186.	27.6	792
3	Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) in the Liver – Update 2012. Ultrasound in Medicine and Biology, 2013, 39, 187-210.	1.5	652
4	The EFSUMB Guidelines and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound (CEUS) in Non-Hepatic Applications: Update 2017 (Long Version). Ultraschall in Der Medizin, 2018, 39, e2-e44.	1.5	627
5	Imaging Medullary Thyroid Carcinoma with Persistent Elevated Calcitonin Levels. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4185-4190.	3.6	246
6	How to perform Contrast-Enhanced Ultrasound (CEUS). Ultrasound International Open, 2018, 04, E2-E15.	0.6	222
7	Guidelines and Good Clinical Practice Recommendations for Contrast-Enhanced Ultrasound (CEUS) in the Liver–Update 2020 WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Ultrasound in Medicine and Biology, 2020, 46, 2579-2604.	1.5	210
8	Advanced Hepatocellular Carcinoma: Early Evaluation of Response to Bevacizumab Therapy at Dynamic Contrast-enhanced US with Quantification—Preliminary Results. Radiology, 2011, 258, 291-300.	7.3	201
9	Gastrointestinal Stromal Tumors Treated with Imatinib: Monitoring Response with Contrast-Enhanced Sonography. American Journal of Roentgenology, 2006, 187, 1267-1273.	2.2	183
10	Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography. Clinical Cancer Research, 2010, 16, 1216-1225.	7.0	170
11	To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: Pilot study using dynamic contrast-enhanced Doppler ultrasound. European Journal of Cancer, 2006, 42, 2472-2479.	2.8	160
12	Imaging of perfusion using ultrasound. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 65-85.	6.4	160
13	Dynamic contrast-enhanced ultrasonography (DCE-US) with quantification of tumor perfusion: a new diagnostic tool to evaluate the early effects of antiangiogenic treatment. European Radiology, Supplement, 2007, 17, 89-98.	1.4	138
14	Phase I Trial of Sorafenib in Combination with IFN α-2a in Patients with Unresectable and/or Metastatic Renal Cell Carcinoma or Malignant Melanoma. Clinical Cancer Research, 2007, 13, 1801-1809.	7.0	136
15	Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) in the Liver – Update 2020 – WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Ultraschall in Der Medizin, 2020, 41, 562-585.	1.5	130
16	Validation of Dynamic Contrast-Enhanced Ultrasound in Predicting Outcomes of Antiangiogenic Therapy for Solid Tumors. Investigative Radiology, 2014, 49, 794-800.	6.2	121
17	Phase II study of oral masitinib mesilate in imatinib-naÃ⁻ve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). European Journal of Cancer, 2010, 46, 1344-1351.	2.8	118
18	Evaluation of Contrast-Enhanced Color Doppler Ultrasound for the Quantification of Angiogenesis In Vivo. Investigative Radiology, 2001, 36, 50-55.	6.2	94

#	Article	IF	CITATIONS
19	Angiogenesis and tumor growth inhibition by a matrix metalloproteinase inhibitor targeting radiation-induced invasion. Molecular Cancer Therapeutics, 2005, 4, 1717-1728.	4.1	89
20	Advanced Hepatocellular Carcinoma: Early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results. European Journal of Radiology, 2013, 82, e205-e211.	2.6	88
21	Dynamic contrast-enhanced ultrasonography (DCE-US): a new tool for the early evaluation of antiangiogenic treatment. Targeted Oncology, 2010, 5, 53-58.	3.6	84
22	Prognostic Value of Angiogenesis Evaluated with High-Frequency and Color Doppler Sonography for Preoperative Assessment of Melanomas. American Journal of Roentgenology, 2002, 178, 1547-1551.	2.2	77
23	Early Quantitative Evaluation of a Tumor Vasculature Disruptive Agent AVE8062 Using Dynamic Contrast-Enhanced Ultrasonography. Investigative Radiology, 2008, 43, 100-111.	6.2	72
24	Prognostic value of angiogenesis evaluated with high-frequency and colour Doppler sonography for preoperative assessment of primary cutaneous melanomas: correlation with recurrence after a 5 year follow-up period. Cancer Imaging, 2006, 6, 24-29.	2.8	68
25	Standardization of Dynamic Contrast-Enhanced Ultrasound for the Evaluation of Antiangiogenic Therapies. Investigative Radiology, 2012, 47, 711-716.	6.2	64
26	Prognostic value of doppler-ultrasonography in hepatic veno-occlusive disease. Transplantation, 2002, 74, 60-66.	1.0	63
27	Dynamic contrast-enhanced ultrasonography (DCE-US) and anti-angiogenic treatments. Discovery Medicine, 2011, 11, 18-24.	0.5	60
28	Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art. Endocrine-Related Cancer, 2014, 21, R105-R120.	3.1	59
29	Quantitative functional imaging by Dynamic Contrast Enhanced Ultrasonography (DCE-US) in GIST patients treated with masatinib. Investigational New Drugs, 2012, 30, 765-771.	2.6	57
30	Benefits of Contrast-Enhanced Sonography for the Detection of Liver Lesions: Comparison with Histologic Findings. American Journal of Roentgenology, 2008, 190, 683-690.	2.2	55
31	Incorporating radiomics into clinical trials: expert consensus endorsed by the European Society of Radiology on considerations for data-driven compared to biologically driven quantitative biomarkers. European Radiology, 2021, 31, 6001-6012.	4.5	53
32	High-frequency sonography and color Doppler in the management of pigmented skin lesions. Ultrasound in Medicine and Biology, 2003, 29, 875-879.	1.5	48
33	Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib) Tj ETQq1 New Drugs, 2010, 28, 199-202.	1 0.7843 2.6	14 rgBT /Ov 48
34	New Hemodynamic Approach to Angiogenesis. Investigative Radiology, 1999, 34, 194-198.	6.2	45
35	Dynamic Contrast-Enhanced Ultrasound Parametric Maps to Evaluate Intratumoral Vascularization. Investigative Radiology, 2015, 50, 212-217.	6.2	44
36	Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2013, 19, 4832-4842.	7.0	43

#	Article	IF	CITATIONS
37	Can we trust the calculation of texture indices of <scp>CT</scp> images? A phantom study. Medical Physics, 2018, 45, 1529-1536.	3.0	41
38	Methodology for Quantifying Interactions Between Perfusion Evaluated by DCE-US and Hypoxia Throughout Tumor Growth. Ultrasound in Medicine and Biology, 2007, 33, 549-560.	1.5	39
39	Estimation of intra-operator variability in perfusion parameter measurements using DCE-US. World Journal of Radiology, 2011, 3, 70.	1.1	36
40	Assessing the Response to Targeted Therapies in Renal Cell Carcinoma: Technical Insights and Practical Considerations. European Urology, 2014, 65, 766-777.	1.9	32
41	Assessment of Quantitative Perfusion Parameters by Dynamic Contrast-Enhanced Sonography Using a Deconvolution Method. Journal of Ultrasound in Medicine, 2012, 31, 595-608.	1.7	31
42	New Ultrasound Techniques Challenge the Diagnosis of Sinusoidal Obstruction Syndrome. Ultrasound in Medicine and Biology, 2018, 44, 2171-2182.	1.5	31
43	Validation of a New Method for Quantifying In Vivo Murine Tumor Necrosis by Sonography. Investigative Radiology, 2004, 39, 350-356.	6.2	29
44	Molecular Ultrasound Imaging Using Contrast Agents Targeting Endoglin, Vascular Endothelial Growth Factor Receptor 2 and Integrin. Ultrasound in Medicine and Biology, 2015, 41, 197-207.	1.5	28
45	CT Texture Analysis Challenges: Influence of Acquisition and Reconstruction Parameters: A Comprehensive Review. Diagnostics, 2020, 10, 258.	2.6	27
46	Study of Intrapatient Variability and Reproducibility of Quantitative Tumor Perfusion Parameters Evaluated With Dynamic Contrast-Enhanced Ultrasonography. Investigative Radiology, 2017, 52, 148-154.	6.2	25
47	Radiofrequency Thermal Ablation of Breast Cancer Local Recurrence: A Phase II Clinical Trial. Annals of Surgical Oncology, 2008, 15, 3222-3226.	1.5	24
48	Imaging of melanoma: usefulness of ultrasonography before and after contrast injection for diagnosis and early evaluation of treatment. Clinical, Cosmetic and Investigational Dermatology, 2011, 4, 1.	1.8	24
49	Doppler US with perfusion software and contrast medium injection in the early evaluation of radiofrequency in breast cancer recurrences: A prospective phase II study. European Journal of Radiology, 2005, 56, 376-381.	2.6	23
50	Combination of HIFU therapy with contrast-enhanced sonography for quantitative assessment of therapeutic efficiency on tumor grafted mice. Ultrasound in Medicine and Biology, 2006, 32, 729-740.	1.5	23
51	Virtual Patients and Sensitivity Analysis of the Guyton Model of Blood Pressure Regulation: Towards Individualized Models of Whole-Body Physiology. PLoS Computational Biology, 2012, 8, e1002571.	3.2	23
52	Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma. Investigational New Drugs, 2010, 28, 690-693.	2.6	22
53	In vivoechographic evidence of tumoral vascularization and microenvironment interactions in metastatic orthotopic human neuroblastoma xenografts. International Journal of Cancer, 2005, 113, 881-890.	5.1	21
54	In vitro evaluation of the impact of ultrasound scanner settings and contrast bolus volume on time–intensity curves. Ultrasonics, 2012, 52, 12-19.	3.9	21

#	Article	IF	CITATIONS
55	Radiologic Assessment of Intranodal Vascularity in Head and Neck Squamous Cell Carcinoma. Investigative Radiology, 1996, 31, 673-679.	6.2	20
56	Ultrasound Molecular Imaging of Renal Cell Carcinoma: VEGFR targeted therapy monitored with VEGFR1 and FSHR targeted microbubbles. Scientific Reports, 2020, 10, 7308.	3.3	18
57	In Vitro Echogenicity Characterization of Poly[lactide-coglycolide] (PLGA) Microparticles and Preliminary In Vivo Ultrasound Enhancement Study for Ultrasound Contrast Agent Application. Investigative Radiology, 2005, 40, 536-544.	6.2	15
58	A new functional imaging technique for the early functional evaluation of antiangiogenic treatment: dynamic contrast-enhanced ultrasonography (DCE-US). Targeted Oncology, 2008, 3, 111-117.	3.6	13
59	Early evaluation of targeted drugs using dynamic contrast-enhanced ultrasonography for personalized medicine. Future Oncology, 2012, 8, 1215-1218.	2.4	13
60	Evaluation of Treatment Response in Patients with Metastatic Renal Cell Carcinoma: Role of State-of-the-Art Cross-Sectional Imaging. Current Urology Reports, 2012, 13, 70-81.	2.2	12
61	Combining functional imaging and interstitial pressure measurements to evaluate two anti-angiogenic treatments. Investigational New Drugs, 2012, 30, 144-156.	2.6	10
62	A Novel Microflow Phantom Dedicated to Ultrasound Microvascular Measurements. Ultrasonic Imaging, 2018, 40, 325-338.	2.6	10
63	Impact of the arterial input function on microvascularization parameter measurements using dynamic contrast-enhanced ultrasonography. World Journal of Radiology, 2012, 4, 291.	1.1	10
64	A New Ultrasound Principle for Characterizing Erythrocyte Aggregation. Investigative Radiology, 2002, 37, 413-420.	6.2	8
65	Comparison of new ultrasound index with laser reference and viscosity indexes for erythrocyte aggregation quantification. Ultrasound in Medicine and Biology, 2003, 29, 789-799.	1.5	8
66	Acoustic characterization of a new trisacryl contrast agent. Part I: In vitro study. Ultrasonics, 2008, 48, 16-25.	3.9	8
67	Toward a Standardization of Ultrasound Scanners for Dynamic Contrast-Enhanced Ultrasonography: Methodology and Phantoms. Ultrasound in Medicine and Biology, 2017, 43, 2670-2677.	1.5	7
68	Lightweight U-Net For Lesion Segmentation In Ultrasound Images. , 2021, , .		7
69	Sorafenib plus dacarbazine in solid tumors: a phase I study with dynamic contrast-enhanced ultrasonography and genomic analysis of sequential tumor biopsy samples. Investigational New Drugs, 2014, 32, 312-322.	2.6	6
70	Abstract LB-302: A comprehensive study of translational research and safety exploration of the vascular disrupting agent (VDA) AVE8062 in combination with cisplatin administered every 3 weeks to patients with advanced solid tumors. , 2008, , .		5
71	Evaluation with DCE-US of antiangiogenic treatments in 539 patients allowing the selection of one surrogate marker correlated to overall survival Journal of Clinical Oncology, 2012, 30, 4618-4618.	1.6	5

Follow-up of Oncology Patients Undergoing Chemotherapy. , 2006, , 77-88.

#	Article	IF	CITATIONS
73	Acoustic characterization of a new trisacryl contrast agent. Part II: Flow phantom study and in vivo quantification. Ultrasonics, 2008, 48, 26-34.	3.9	2
74	Study of the reliability of quantification methods of dynamic contrast-enhanced ultrasonography: numerical modeling of blood flow in tumor microvascularization. Physics in Medicine and Biology, 2018, 63, 17NT01.	3.0	2
75	New method for quantification of intratumoral heterogeneity: a feasibility study on Ktrans maps from preclinical DCE-MRI. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2021, 34, 845-857.	2.0	2
76	Molecular Imaging to Predict Response to Targeted Therapies in Renal Cell Carcinoma. Contrast Media and Molecular Imaging, 2017, 2017, 1-8.	0.8	1
77	Methodological Study to Investigate the Potential of Ultrasound-Based Elastography and Texture as Biomarkers to Monitor Liver Tumors. Diagnostics, 2020, 10, 811.	2.6	1
78	Ľimagerie de contraste ultrasonore pour ľévaluation précoce des thérapeutiques ciblées. , 2007, ,	81-86.	1
79	Advanced Ultrasound Imaging for Patients in Oncology: DCE-US. Recent Results in Cancer Research, 2020, 216, 765-771.	1.8	1
80	Prediction of Early Response to Immunotherapy: DCE-US as a New Biomarker. Cancers, 2022, 14, 1337.	3.7	0